Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

Oncotarget

Volumn 8, Issue 7, 2017, Pages 12501-12516

  Normanno, Nicola ^a   Denis, Marc G ^b   Thress, Kenneth S ^c   Ratcliffe, Marianne ^c   Reck, Martin ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c ASTRAZENECA   (United Kingdom)

^d Member of the German Center for Lung Research   (Germany)

Author keywords

CtDNA; EGFR; NSCLC; T790M

Indexed keywords

CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; DNA; EGFR PROTEIN, HUMAN;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER GROWTH; DNA EXTRACTION; EGFR GENE; GENE MUTATION; HUMAN; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE; REVIEW; SENSITIVITY AND SPECIFICITY; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG NEOPLASMS; MUTATION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; STANDARDS;

CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS;

EID: 85012921202     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13915     Document Type: Review

References (108)

1. National Institute for Health and Care Excellence. Diagnosis and staging of lung cancer. Available at: http://pathways. nice.org.uk/pathways/lung-cancer#path = view%3A/pathways/lung-cancer/diagnosis-and-staging-of-lungcancer. xml&content = view-quality-statement%3Aqualitystatements-tissue-diagnosis. Last updated 2016. Accessed 4 July 2016.
2. Royal College of Physicians. National Lung Cancer Audit annual report 2015 (for the audit period 2014). Available at: https://www.rcplondon.ac.uk/projects/outputs/nlca-annualreport-2015 Last updated 2 December 2015. Accessed 4 July 2016.
3. Huang WL, Wei F, Wong DT, Lin CC and Su WC. The emergent landscape of detecting EGFR mutations using circulating tumor DNA in lung cancer. Biomed Res Int. 2015; 2015: 340732.
4. Sun W, Yuan X, Tian Y, Wu H, Xu H, Hu G and Wu K. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. J Hematol Oncol. 2015; 8: 95.
5. Sánchez-Céspedes M, Monzó M, Rosell R, Pifarré A, Calvo R, López-Cabrerizo MP and Astudillo J. Detection of chromosome 3p alterations in serum DNA of non-smallcell lung cancer patients. Ann Oncol. 1998; 9: 113-116.
6. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K and Nishio K. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 2006; 97: 642-648.
7. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
8. Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A and Milenkova T. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open label, single arm study. Br J Cancer. 2014; 110: 55-62.
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
10. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T and McCormack R. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9: 1345-1353.
11. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier PT, Jackman DM and Jänne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014; 20: 1698-1705.
12. Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E and Meldgaard P. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014; 120: 3896-3901.
13. Wang Z, Chen R, Wang S, Zhong J, Wu M, Zhao J, Duan J, Zhuo M, An T, Wang Y, Bai H and Wang J. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFRTKI treatment in advanced NSCLC. PLoS One. 2014; 9: e110780.
14. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonsmall cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21: 560-562.
15. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz Jr LA, Goodman SN, David KA, Juhl H, Kinzler KW and Vogelstein B. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102: 16368-16373.
16. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo Jr BW, Alizadeh AA et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20: 548-554.
17. Diaz Jr LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32: 579-586.
18. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM and Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998; 17: 89-97.
19. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014; 6: 224ra24.
20. Anker P, Stroun M and Maurice PA. Spontaneous extracellular synthesis of DNA released by human blood lymphocytes. Cancer Res. 1976; 36: 2832-2839.
21. Krug AK, Karlovich C, Koestler T, Bentink S, Brinkmann K, Spiel A, Emenegger J, Noerholm M, O'Neill V, Sequist LV, Soria J, Golmand JW, Camidge DR et al. Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs. Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA, 5-9 November, 2015.
22. Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F, Xu L and Yin R. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a metaanalysis. Cancer Epidemiol Biomarkers Prev. 2015; 24: 206-212.
23. Qian X, Liu J, Sun Y, Wang M, Lei H, Luo G, Liu X, Xiong C, Liu D, Liu J and Tang Y. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer. Oncotarget. 2016; 7: 29154-29165. doi: 10.18632/oncotarget.8684.
24. Luo J, Shen L and Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep. 2014; 4: 6269.
25. Li Z, Zhang Y, Bao W and Jiang C. Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis. Target Oncol. 2014; 9: 381-388.
26. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulundari L, Konstantin Konstantinovich L, Hudoyo A, Ratcliffe M, McCormack R and Reck M. Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) with advanced non-small-cell lung cancer (aNSCLC) of adenocarcinoma (ADC) or non-ADC histology: IGNITE study. Ann Oncol. 2015; 26 (Suppl 1): i29-i30.
27. Reck M, Hagiwara K, Han B, Tjulandin S, Grohe C, Yokoi T, Morabito A, McCormack R, Ratcliffe M and Normanno N. Investigating the utility of circulating-free tumourderived DNA (ctDNA) in plasma for the detection of epidermal growth factor receptor (EGFR) mutation status in European and Japanese patients (pts) with advanced non-small-cell lung cancer (aNSCLC). Ann Oncol. 2015; 26 (Suppl 1): i58-i59.
28. El Messaoudi S, Rolet F, Mouliere F and Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013; 424: 222-230.
29. Vallée A, Marcq M, Bizieux A, Kouri CE, Lacroix H, Bennouna J, Douillard JY and Denis MG. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer. 2013; 82: 373-374.
30. Lam NY, Rainer TH, Chiu RW and Lo YM. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem. 2004; 50: 256-257.
31. Beutler E, Gelbart T and Kuhl W. Interference of heparin with the polymerase chain reaction. Biotechniques. 1990; 9: 166.
32. Garcia-Murillas I, Shiavon G, Hrebien S, Oleary B, Morden J, Smith IE and Turner N. Development and validation of multiplex digital PCR assays on circulating tumor DNA in advanced breast cancer: implementation for clinical routine use. Ann Oncol. 2015; 26 (Suppl 3): iii16.
33. Toro PV, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, Cravero K, Chu D, Zabransky DJ, Wong HY, Croessmann S, Parsons H, Hurley PJ et al. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem. 2015; 48: 993-998.
34. Denis MG, Knol AC, Théoleyre S, Vallée A and Dréno B. Efficient detection of BRAF mutation in plasma of patients after long-term storage of blood in cell-free DNA blood collection tubes. Clin Chem. 2015; 61: 886-888.
35. Chiu RW, Poon LL, Lau TK, Leung TN, Wong EM and Lo YM. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem. 2001; 47: 1607-1613.
36. Swinkels DW, Wiegerinck E, Steegers EA and de Kok JB. Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin Chem. 2003; 49: 525-526.
37. Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P and Pastorino U. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst. 2005; 97: 1848-1850.
38. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E and Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8: 823-859.
39. Fleischhacker M, Schmidt B, Weickmann S, Fersching DM, Leszinski GS, Siegele B, Stotzer OJ, Nagel D and Holdenrieder S. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. 2011; 412: 2085-2088.
40. Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M and Kohlmann A. Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS One. 2016; 11: e0150197.
41. Reck M, Hagiwara K, Tjulandin S, Han B, McWalter G, McCormack R and Normanno N. Investigating the utility of plasma derived circulating free DNA for the detection of epidermal growth factor receptor (EGFR) mutations in European and Japanese patients with advanced non-smallcell lung cancer (NSCLC): ASSESS study design. J Thorac Oncol. 2013; 8 (Suppl 2): 482.
42. Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB and Johnson BE. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst. 2014; 106: dju214.
43. Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M and Barrett JC. EGFR mutation detection in ctDNA from NSCLC patient plasma: a crossplatform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015; 90: 509-515.
44. Kim S-W, Wu Y-L, Nakgawa K, Yang J-J, Ahn M-J, Wang J, Yang JC-H, Lu Y, Atagi S, Ponce S, Soria J-C, Mok T, Shi X et al. Retrospective analysis of ctDNA EGFR mutations in the Phase III, randomized IMPRESS study. J Thorac Oncol. 2015; 10 (Suppl 2): S204-S205.
45. Karlovich CA, Goldman J, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel DR, Soria JC, Solomon B, Camidge DR et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686). Clin Cancer Res. 2016; 22: 2386-2395.
46. Normanno N, Hagiwara K, Han B, Tjulandin S, Grohé C, Yokoi T, Morabito A, Novello S, Arriola E, Molinier O, McCormack RM, Ratcliffe M and Reck M. Local diagnostic practices for advanced non-small-cell lung cancer in Europe and Japan: ASSESS study. J Thorac Oncol. 2015; 10 (Suppl 2): 197-198.
47. Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y, McCormack R, Gu Y and Liu X. Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced nonsmall cell lung cancer. J Mol Diagn. 2015; 17: 265-272.
48. Huang Z, Wang Z, Bai H, Wu M, An T, Zhao J, Yang L, Duan J, Zhuo M, Wang Y, Wang S and Wang J. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Caner. 2012; 3: 334-340.
49. Jing CW, Wang Z, Cao HX, Ma R and Wu JZ. High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2014; 14: 6619-6623.
50. Brevet M, Johnson ML, Azzoli CG and Ladanyi M. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer. 2011; 73: 96-102.
51. Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Kobayashi N, Hayashi S, Hosomi T, Hirai M, Sueoka E and Kimura S. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol. 2012; 7: 1369-1381.
52. Zhao X, Han RB, Zhao J, Wang J, Yang F, Zhong W, Zhang L, Li LY and Wang MZ. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration. 2013; 85: 119-125.
53. Uchida J, Kato K, Kukita Y, Kumagai T, Nishino K, Daga H, Nagatomo I, Inoue T, Kimura M, Oba S, Ito Y, Takeda K and Imamura F. Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem. 2015; 61: 1191-1196.
54. Yao Y, Liu J, Li L, Yuan Y, Nan K, Wu X, Zhang Z, Wu Y, Li X, Zhu J, Meng X, Wei L, Chen J et al. Detection of circulating tumor DNA in patients with advanced nonsmall cell lung cancer. Oncotarget. 2016; doi: 10.18632/oncotarget.12883.
55. Pasquale R, Fenizia F, Esposito Abate R, Sacco A, Esposito C, Forgione L, Rachiglio AM, Bevilacqua S, Montanino A, Franco R, Rocco G, Botti G, Denis MG et al. Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics. 2015; 16: 1135-1148.
56. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-967.
57. Yam I, Lam DC, Chan K, Chung-Man HJ, Ip M, Lam WK, Chan TK and Chan V. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients. J Thorac Oncol. 2012; 7: 1131-1140.
58. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T and Fukuoka M. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol. 2012; 7: 115-121.
59. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, Tang C, Ellison G, McCormack R and Ji Q. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013; 66: 1065-1069.
60. Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J, Khalil A, Nexo E and Sorensen BS. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer. 2014; 14: 294.
61. Liu Y, Liu B, Li XY, Li JJ, Qin HF, Tang CH, Guo WF, Hu HX, Li S, Chen CJ, Liu B, Gao HJ and Liu XQ. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res. 2011; 30: 111.
62. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC and Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989; 17: 2503-2516.
63. Whitcombe D, Theaker J, Guy SP, Brown T and Little S. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol. 1999; 17: 804-807.
64. Hsiue EH, Lee JH, Lin CC and Yang JC. Profile of the therascreen® EGFR RGQ PCR Kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagn. 2016; Epub ahead of print.
65. Wittung P, Nielsen PE, Buchardt O, Egholm M and Norden B. DNA-like double helix formed by peptide nucleic acid. Nature. 1994; 368: 561-563.
66. Dressman D, Yan H, Traverso G, Kinzler KW and Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003; 100: 8817-8822.
67. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC, Kitano TK, Hodel MR, Petersen JF et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011; 83: 8604-8610.
68. Ma C, Wei S and Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2011; 3: 10-18.
69. Yung TK, Chan KC, Mok TS, Tong J, To KF and Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009; 15: 2076-2084.
70. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC and Jänne PA. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced nonsmall-cell lung cancer. J Clin Oncol. 2016; 34: 3375-3382.
71. Thress K, Yang J, Ahn M, Kim D, Kim S, Ohe Y, Planchard D, Brant R, Carr H, Dearden S, Jenkins S, Cantarini M, Ghiorghiu S et al. Levels of EGFR T790M in plasma DNA as a predictive biomarker for response to AZD9291, a mutant-selective EGFR kinase inhibitor. Ann Oncol. 2014; 25 (Suppl 4): iv426-iv470.
72. Ohira T, Sakai K, Matsubayashi J, Kajiwara N, Kakihana M, Hagiwara M, Hibi M, Yoshida K, Maeda J, Ohtani K, Nagao T, Nishio K and Ikeda N. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small-cell lung cancer. Cancer Sci. 2016; 107: 1660-1666.
73. Kukita Y, Matoba R, Uchida J, Hamakawa T, Doki Y, Imamura F and Kato K. High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients. DNA Res. 2015; 22: 269-277.
74. Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res. 2014; 20: 4613-4624.
75. Goldberg SB, Narayan A, Carriero NJ, Nemati R, Bommakanti A, Wurtz A, Boffa DJ, Decker RH, Herbst RS, Juergensmeier JM, Politi KA, Gettinger SN and Patel A. Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma. J Clin Oncol (Meeting Abstracts). 2014; 32 (15 Suppl):
76. Collisson E, Mortimer S, Sebisanovic D, Mokhtari R, Bakhtiari S, Lopez R, Gadde DM, Vidamo MM, Patel H, Bahram GK, Eltoukhy H, Lanman RB and Talasaz A. Biopsy-free comprehensive tumor profiling of 1, 000+ consecutive cancer patients using CLIA-certified commercial test and its clinical utility. Poster presented at the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, USA, 20 April, 2015.
77. Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, Wiedenmann B, Norton JA, Lee M, Jeffrey SS and Poultsides GA. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget. 2015; 6: 2549-2561. doi: 10.18632/oncotarget.3041.
78. Rachiglio AM, Abate RE, Sacco A, Pasquale R, Fenizia F, Lambiase M, Morabito A, Montanino A, Rocco G, Romano C, Nappi A, Iaffaioli RV, Tatangelo F et al. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget. 2016; doi: 10.18632/oncotarget.10704.
79. Villaflor V, Won B, Nagy R, Banks K, Lanman RB, Talasaz A and Salgia R. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016; doi: 10.18632/oncotarget.11801.
80. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016; 7: 11815.
81. Khoo C, Rogers TM, Fellowes A, Bell A and Fox S. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res. 2015; 4: 126-141.
82. Normanno N, Brown H, Haddad V, Ratcliffe M, McCormack R, Tjulandin S, Hagiwara K, Han B and Reck M. 580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience. Journal of Thoracic Oncology 2016; 11: S151.
83. Tjulandin S, Han B, Hagiwara K, Normanno N, Wulandari L, Laktionov K, Hudoyo A, He Y, Zhang YP, Wang M-Z, Liu CY, Ratcliffe M, McCormack R et al. Local diagnostic practices for advanced non-small-cell lung cancer in Asia-Pacific and Russia: IGNITE study. J Thorac Oncol. 2015; 10 (Suppl 2): 401-402.
84. Spicer J, Tischer B and Peters M. EGFR mutation testing and oncologist treatment choice in advanced NSCLC: global trends and differences. Ann Oncol. 2015; 26 (Suppl 1): i60.
85. Denis MG, Masson P, Vallée A, Pigeanne T and Lacroix H. EGFR mutation detection in plasma of lung tumor patients in the absence of contributive tissue is a relevant alternative for prescription of tyrosine kinase inhibitors in a routine clinical setting. Annal Oncol. 2015; 26 (Suppl 1): i33.
86. Husain H, Kosco K, Guerrero S, Lu TT, Vibat CRT, Erlander MG and Melnikova V. Detection of EGFR T790M mutation in urinary circulating tumor DNA from metastatic non-small-cell lung cancer patients. Ann Oncol. 2015; 26 (Suppl 1): i10.
87. Chen S, Zhao J, Cui L and Liu Y. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clin Transl Oncol. 2016;
88. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol. 2016; 11: 1690-1700
89. Pan W, Gu W, Nagpal S, Gephart MH and Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015; 61: 514-522.
90. Wang Y, Springer S, Zhang M, McMahon KW, Kinde I, Dobbyn L, Ptak J, Brem H, Chaichana K, Gallia GL, Gokaslan ZL, Groves ML, Jallo GI et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015; 112: 9704-9709.
91. Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, Iuchi T, Yokoi S, Kimura H and Iizasa T. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol. 2011; 6: 1215-1220.
92. Zhao J, Ye X, Xu Y, Chen M, Zhong W, Sun Y, Yang Z, Zhu G, Gu Y and Wang M. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. Cancer Chemother Pharmacol. 2016; Epub ahead of print.
93. Yang H, Cai L, Zhang Y, Tan H, Deng Q, Zhao M and Xu X. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn. 2014; 16: 558-563.
94. Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Janne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res. 2016; 22: 1103-1110.
95. Sequist LV, Goldman JW, Wakelee HA, Camidge DR, Yu HA, Varga A, Solomon B, Oxnard GR, Ou S-HI, Papadimitrakopoulou V, Chao BH, Liu SV, Reckamp KL et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol (Meeting Abstracts). 2015; 33 (15 Suppl): 8001.
96. Ramalingam SS, Yang JC-H, Lee CK, Kurata T, Kim D-W, John T, Nogami N, Ohe Y, Rukazenkov Y, Frewer P, Cantarini M, Ghiorghiu S and Janne AP. AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): results from a phase I expansion cohort. J Clin Oncol (Meeting Abstracts). 2015; 33 (15 Suppl): 8000.
97. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 2015; 5: 713-722.
98. Thress K, Brant R, Carr H, Brown H, Dearden SP, Jenkins S, Hammett T, Cantarini M, Ghiorghiu S and Barrett JC. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of technologies to support the clinical development of AZD9291. Lung Cancer. 2015; 90: 509-515:
99. Imamura F, Uchida J, Kukita Y, Kumagai T, Nishino K, Inoue T, Kimura M, Oba S and Kato K. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer. 2016; 94: 68-73.
100. Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del GM, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De TM et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol. 2015; 10: 1437-1443.
101. Marcq M, Vallee A, Bizieux A and Denis MG. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors? J Thorac Oncol. 2014; 9: e49-e50.
102. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B and Diaz LA, Jr. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14: 985-990.
103. Imamura F, Uchida J, Kukita Y, Kumagai T, Nishino K, Inoue T, Kimura M and Kato K. Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment. Oncotarget. 2016; doi: 10.18632/oncotarget.12373.
104. Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, Muley T, Thomas M and Sültmann H. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Sci Rep. 2016; 6: 33505.
105. Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Janne PA and Oxnard GR. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016; 2: 1014-1022.
106. Valleé A, Audigier-Valette C, Herbreteau G, Merrien J, Tessonnier L, Théoleyre S and Denis MG. Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation. Lung Cancer. 2016; 91: 73-74.
107. Beiter T, Fragasso A, Hudemann J, Niess AM and Simon P. Short-term treadmill running as a model for studying cellfree DNA kinetics in vivo. Clin Chem. 2011; 57: 633-636.
108. Han B, Tjulandin S, Normanno N, Hagiwara K, Reck M, McWalter G and McCormack R. A diagnostic study to determine the prevelance of epidermal growth factor receptor (EGFR) mutations in Asian and Russian patients with non-small-cell lung cancer (NSCLC) of adenocarcinoma and non-adenocarcinoma histology: IGNITE study design. J Thorac Oncol. 2013; 8 (Suppl 2): 1097.